← Back to Search

Tremelimumab for Tumors

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. actual median study duration was 2.2 years.
Awards & highlights

Study Summary

This trial will provide access to the drug tremelimumab for patients who have previously received it in a clinical trial.

Eligible Conditions
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Kidney Cancer
  • Tumors
  • Melanoma and Other Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. actual median study duration was 2.2 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. actual median study duration was 2.2 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy Endpoints: Survival
Efficacy Endpoints: Tumor Status: Alive With Disease (AWD) or no Evidence of Disease (NED)
Safety Endpoints: Grade 3 or 4 Tremelimumab-related Adverse Events to Tremelimumab.
+2 more
Secondary outcome measures
Disease Free Survival

Side effects data

From 2023 Phase 2 trial • 37 Patients • NCT00378482
11%
Rash
8%
Pruritus
5%
Hypothyroidism
3%
Pulmonary Granuloma
3%
Urinary Tract Infection
3%
Prostate cancer
3%
Diarrhea
3%
Medical Device Complication
3%
Cholecystitis
3%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tremelimumab 15mg/kg

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Drug: CP-675,206 (Tremelimumab)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CP-675,206 (Tremelimumab)
2007
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,266 Previous Clinical Trials
288,605,945 Total Patients Enrolled
AstraZeneca AstraZenecaStudy DirectorAstraZeneca
81 Previous Clinical Trials
55,612 Total Patients Enrolled
Peter Langmuir, Dir.Medic.ScienceStudy DirectorAstraZeneca

Media Library

CP-675,206 (Tremelimumab) Clinical Trial Eligibility Overview. Trial Name: NCT00378482 — Phase 2
Colorectal Cancer Research Study Groups: 1
Colorectal Cancer Clinical Trial 2023: CP-675,206 (Tremelimumab) Highlights & Side Effects. Trial Name: NCT00378482 — Phase 2
CP-675,206 (Tremelimumab) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00378482 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age limit for this trial extend past 80 years old?

"This clinical study is currently looking for participants that fall in the age range of 18 to 130 years old."

Answered by AI

How many people are currently signed up to participate in this experiment?

"Unfortunately, this trial is no longer recruiting patients. If you were looking for other studies, 5393 different clinical trials are actively seeking enrolment from individuals with colorectal cancer and 94 studies are investigating CP-675,206 (Tremelimumab)."

Answered by AI

In how many different medical facilities is this research project being conducted currently?

"Currently, this research is being conducted at 9 different locations which include Tampa, Houston and Madison. If you are considering enrolling in the study, please note that it might be most convenient for you to select a location closest to your home to minimize travel demands."

Answered by AI

Is CP-675,206 (Tremelimumab) deadly for human beings?

"CP-675,206 (Tremelimumab) is a medication that received a score of 2 for safety. This is because there is some evidence collected in Phase 2 trials to support the assertion that it is safe, but no data yet to suggest that it effective."

Answered by AI

Have there been other studies like this one in the past?

"As of right now, there are 94 active clinical trials for CP-675,206 (Tremelimumab) in 263 different cities and 48 countries. The first ever trial for this medication was back in 2007 and it completed its Phase 2 drug approval stage that year. 37 people participated in the study which was sponsored by AstraZeneca. Since 2007, 64 other similar trials have been conducted."

Answered by AI

Who might be most likely to see benefits from participating in this medical study?

"Eligibility requirements for this clinical trial include a cancer diagnosis of colorectal cancer and being between 18 to 130 years old. Currently, there are 37 patients enrolled in the study."

Answered by AI

Are we still enrolling patients for this clinical trial?

"This study, which was first posted on March 5th 2007, is not looking for any more participants as of October 6th 2022. However, there are plenty of other trials (5487 to be exact) that are still recruiting patients."

Answered by AI

Is CP-675,206 (Tremelimumab) a new drug being trialed?

"CP-675,206 (Tremelimumab) was first trialled in 2007 at Research Site. As of now, there have been 64 completed clinical trials. At the moment, there are 94 active studies; a significant number of these are based in Tampa, Florida."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
2007. "A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00378482.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top